+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.

Age: 18Years +All Genders
113 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of a drug called BMS-986368 in adults with Multiple Sclerosis Spasticity. This Phase 2 trial compares three different doses of the drug administered orally against a placebo. The study focuses on participants aged 18 to 70 who have a confirmed diagnosis of multiple sclerosis with spasticity lasting at least 6 months. Participants are randomly assigned to one of four groups three groups receive different doses of BMS-986368, and one group receives a placebo. The drug is given on specified days, though exact dosing schedules are not detailed in the summary. The study is double-blind, meaning neither participants nor most study staff know who receives the active drug or placebo. This treatment phase is planned to last at least 6 weeks, during which various assessments will take place. During the study, participants undergo evaluations including the Modified Ashworth Scale for spasticity, Numeric Rating Scale for spasticity severity, Timed 25-Foot Walk, and other clinical assessments. Blood samples will be collected to measure plasma levels of BMS-986368. Safety is closely monitored up to 16 weeks, including adverse events and withdrawal symptoms. The main outcome measure tracks changes in spasticity score at 6 weeks. Participants progress will be assessed through scheduled visits, and the total participation duration may extend beyond the treatment period for safety follow-up.

Age: 18Years - 70YearsAll GendersPhase 2
61 locations
E

Actively Recruiting

Researchers are evaluating a modified regimen of ublituximab for adults with relapsing multiple sclerosis RMS in this phase 3b study. The study aims to assess the medicines impact on brain lesions visible on MRI scans and its pharmacokinetics, particularly in participants who had limited benefit from prior anti-CD20 therapies. The trial includes three parts Part A is open-label and single-arm, Part B is randomized, double-blind, and placebo-controlled, and Part C is open-label and single-arm. Participants receive ublituximab through intravenous infusions, with dosing schedules varying by study part. In Part A, infusions occur on Day 1 of Week 1, Day 15 if applicable, and at Week 24. In Part B, participants receive either 600 mg ublituximab on Week 1 Day 1, placebo on Day 15, and 450 mg ublituximab at Week 24, or 150 mg ublituximab on Week 1 Day 1 followed by 450 mg on Day 15 and Week 24. Part C participants receive 150 mg on Week 1 Day 1 and 450 mg on Day 15 and Week 24. During the study, participants are monitored for changes in T1 Gadolinium-enhancing lesions on MRI from baseline to Week 48, infusion-related reactions, treatment satisfaction, and pharmacokinetics over 16 weeks. Safety and efficacy assessments include neurological stability, clinical exams, and questionnaires. The total study duration extends to at least 48 weeks, with detailed follow-up and monitoring to evaluate treatment impact and participant health.

Age: 18Years - 65YearsAll GendersPhase 3
51 locations